Shots:

• Novartis to receive up front and up to $291M upon achievement of certain development and commercial milestones- as well as royalties on annual net sales. Gilead acquires exclusive WW rights to develop and commercialize novel small molecules against three undisclosed targets
• The focus of the agreement is to develop therapies for treat human rhinovirus- influenza and herpes viruses with limited therapeutic options- further improving QoL  
• Biktarvy (qd) is an INSTI-based triple-therapy STR combining bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg (BIC/FTC/TAF) approved for HIV-1 Infection in Japan. Additionally- Gilead has an antiviral portfolio which includes therapies for HIV- hepatitis B and hepatitis C- as well as influenza infection

Click here to read full press release/ article | Ref: Gilead | Image: Leo Associates